Stallion India Fluorochemicals Limited Approves Grant of Employee Stock Options
Stallion India Fluorochemicals Limited announced the approval of a significant tranche of Employee Stock Options (ESOPs) following a resolution passed by its Nomination and Remuneration Committee (NRC) on April 13, 2026.The NRC approved the grant of ESOPs to eligible employees under the Stallion Employee Stock Option Plan 2025.
The key financial details of the ESOP grant are as follows:
| Scheme | Total Options | Exercise Price per Option | Vesting Period |
|---|---|---|---|
| Stallion Employee Stock Option Plan 2025 | 15,86,505/- (Fifteen lakh eighty-six thousand five hundred five Only) | INR 10/- | Vesting over 1 year (100%) |
The total options granted amount to 15,86,505/- (Fifteen lakh eighty-six thousand five hundred five Only) and are exercisable into not more than 15,86,505/- (Fifteen lakh eighty-six thousand five hundred five Only) equity shares of face value of Re. 10/- (Rupee One Only) each fully paid-up. The exercise price for each option is determined at Rs. 10/- (Rupees Ten Only).
The significant terms of the grant specify that options granted must have a minimum vesting period of one year from the date of grant. All granted options are subject to the stipulated vesting schedule detailed in the respective Grant Letter. Furthermore, any vested options shall remain exercisable within a maximum period of four years from the date of vesting.
STALLION Stock Price Movement
Today, Stallion India Fluorochemicals shares edged higher to close at ₹140.81, successfully gaining 2.83% in post-market trading. The stock saw robust activity, with a total traded volume of 2.51 million shares throughout the session.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.